SCHEMBL762777

SCHEMBL762777

C=COC(=O)c1c[nH]c(C#N)c1-c1ccc([N+](=O)[O-])c(Cl)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
VCAM1 P19320 2/20 0.33
ALDH1A1 P00352 2/20 0.32
MERTK Q12866 2/20 0.32
MAPT P10636 3/20 0.32
LMNA P02545 2/20 0.32
HTT P42858 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
GPR55 Q9Y2T6 1/20 0.32
GAA P10253 1/20 0.31
HPGD P15428 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
MMP1 P03956 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL762317 0.88 ATM (0.33)
SCHEMBL744523 0.85 POLB (0.42) ALDH1A1MAPTLMNANPSR1HPGD
SCHEMBL762325 0.83 KMT2A (0.35) TSHRMAPK1ALDH1A1MAPTLMNA
SCHEMBL762157 0.78 MERTK (0.33) TSHRMAPK1VCAM1ALDH1A1MERTK
SCHEMBL762321 0.75
SCHEMBL765513 0.75 PDGFRB (0.39) TSHRMAPK1VCAM1ALDH1A1MERTK
SCHEMBL276542 0.73 ALDH1A1 (0.39) ALDH1A1MAPTLMNANPSR1GPR55
SCHEMBL15435528 0.71 SIRT5 (0.41)
SCHEMBL762315 0.71 ATM (0.34)
SCHEMBL743085 0.69 POLB (0.42) ALDH1A1MAPTLMNANPSR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138336-B2 Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase BAYER HEALTHCARE LLC (US) 2012-03-20 US disclosed
US-20100273800-A1 PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE BAYER HEALTHCARE LLC 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273800-A1 PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE AURKC, AURKA, PLK1 TSHR 4054/4885MAPK1 1333/4885VCAM1 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.